Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


N.Y. covers OTC Plan B

This article was originally published in The Tan Sheet

Executive Summary

New York Medicaid will cover nonprescription Plan B emergency contraception starting Feb. 1, the Pharmacy Access Partnership states in a same-day announcement. "While most states still require Medicaid enrollees to obtain a prescription for Plan B in order to receive coverage, New York is stepping ahead of the curve to ensure contraceptive parity for all women," the Oakland, Calif.-based nonprofit group says. In August 2006 FDA approved Plan B for over-the-counter sale for consumer ages 18 and older, but maintained prescription-only status for women under 18 (1"The Tan Sheet" Aug. 28, 2006, p. 3)...

You may also be interested in...

Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

Pharma Firms Must Act On Biodiversity Footprinting To Avoid Business Risks

Biodiversity footprinting may still be a new concept for pharmaceutical companies, but they need to put a clear supply chain strategy in place now, particularly as the COP 15 conference in December is expected to discuss mandatory reporting of biodiversity risks, says Luka Brown.

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement Of The Market’

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts